Literature DB >> 24944814

Association between p16(CDKN2A) C540G polymorphism and tumor behavior in prolactinoma: A single-center study.

Soner Cander1, Mutlu Karkucak2, Ozen Oz Gul3, Sebnem Ozemri Sag2, Tahsin Yakut2, Canan Ersoy3, Ercan Tuncel3, Erdinc Erturk3.   

Abstract

Pituitary tumors usually originate as benign sporadic adenomas and develop into invasive and aggressive tumors such as prolactinomas, which are common functioning pituitary adenomas. The aim of the present study was to examine the association between the tumor behavior in prolactinomas and the p16(CDKN2A) gene polymorphism occurring at the 3'-untranslated region of exon 3 (C540G). A total of 104 patients with prolactinoma were included and assigned to two groups based on invasive vs. non-invasive tumor behavior. Ki67 indices were recorded according to histopathology results. Genotypic analysis of the p16(CDKN2A) C540G polymorphism was carried out using a modified polymerase chain reaction-restriction fragment length polymorphism assay. The corresponding frequencies for CC, CG and GG genotypes in non-invasive vs. invasive tumors were 61.5, 30.8, 7.7 and 64.1, 28.2, 7.7%, respectively (not significant). The observed CG genotype frequency was higher compared with previous studies. In addition, the patients with giant adenomas or a high Ki67 index had a higher frequency of the CG genotype as compared with the other subgroups, although the differences were not significant (46.2 and 42.9%, respectively). In conclusion, a higher frequency of the C540G CG genotype of the CDKN2A gene was found among patients with prolactinoma in comparison with previous studies. These frequencies were also higher in the subgroups with elevated Ki67 or giant adenomas. Further studies are required to improve the definition of the role of the CG genotype in the development and progression of tumors in prolactinomas.

Entities:  

Keywords:  CDKN2A C540G polymorphism; invasiveness; prolactinoma; tumor behavior

Year:  2014        PMID: 24944814      PMCID: PMC4051468          DOI: 10.3892/br.2014.281

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  36 in total

1.  Aberrant methylation of EDNRB and p16 genes in hepatocellular carcinoma (HCC) in Taiwan.

Authors:  Li-Sung Hsu; Hsin-Chen Lee; Gar-Yang Chau; Pen-Hui Yin; Chin-Wen Chi; Wing Yiu Lui
Journal:  Oncol Rep       Date:  2006-02       Impact factor: 3.906

2.  The new WHO classification of human pituitary tumors: comments.

Authors:  Dominique Figarella-Branger; Jacqueline Trouillas
Journal:  Acta Neuropathol       Date:  2005-11-23       Impact factor: 17.088

3.  Clinical characterization of familial isolated pituitary adenomas.

Authors:  A F Daly; M-L Jaffrain-Rea; A Ciccarelli; H Valdes-Socin; V Rohmer; G Tamburrano; C Borson-Chazot; B Estour; E Ciccarelli; T Brue; P Ferolla; P Emy; A Colao; E De Menis; P Lecomte; F Penfornis; B Delemer; J Bertherat; J L Wémeau; W De Herder; F Archambeaud; A Stevenaert; A Calender; A Murat; F Cavagnini; A Beckers
Journal:  J Clin Endocrinol Metab       Date:  2006-06-20       Impact factor: 5.958

4.  Frequent loss of the P16INK4a gene product in human pituitary tumors.

Authors:  M Woloschak; A Yu; J Xiao; K D Post
Journal:  Cancer Res       Date:  1996-06-01       Impact factor: 12.701

Review 5.  Genetic basis of endocrine disease: pituitary tumor pathogenesis.

Authors:  I Shimon; S Melmed
Journal:  J Clin Endocrinol Metab       Date:  1997-06       Impact factor: 5.958

6.  Frequent inactivation of the p16 gene in human pituitary tumors by gene methylation.

Authors:  M Woloschak; A Yu; K D Post
Journal:  Mol Carcinog       Date:  1997-08       Impact factor: 4.784

Review 7.  Cyclin-dependent kinase pathways as targets for cancer treatment.

Authors:  Geoffrey I Shapiro
Journal:  J Clin Oncol       Date:  2006-04-10       Impact factor: 44.544

8.  Analysis of G(1)/S checkpoint regulators in metastatic melanoma.

Authors:  I Sauroja; J Smeds; T Vlaykova; R Kumar; L Talve; M Hahka-Kemppinen; K Punnonen; C T Jansèn; K Hemminki; S Pyrhönen
Journal:  Genes Chromosomes Cancer       Date:  2000-08       Impact factor: 5.006

9.  Haplotypes of two variants in p16 (CDKN2/MTS-1/INK4a) exon 3 and risk of squamous cell carcinoma of the head and neck: a case-control study.

Authors:  Yuxin Zheng; Hongbing Shen; Erich M Sturgis; Li-E Wang; Sanjay Shete; Margaret R Spitz; Qingyi Wei
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-07       Impact factor: 4.254

10.  Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation.

Authors:  Jinyun Chen; Donghui Li; Ann M Killary; Subrata Sen; Christopher I Amos; Douglas B Evans; James L Abbruzzese; Marsha L Frazier
Journal:  Ann Surg Oncol       Date:  2008-11-20       Impact factor: 5.344

View more
  3 in total

1.  The Role of p16 and MDM2 Gene Polymorphisms in Prolactinoma: MDM2 Gene Polymorphisms May Be Associated with Tumor Shrinkage.

Authors:  Seda Turgut; Muzaffer Ilhan; Saime Turan; Ozcan Karaman; Ilhan Yaylim; Ozlem Kucukhuseyin; Ertugrul Tasan
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

2.  3'UTR-CDKN2A and CDK4 Germline Variants Are Associated With Susceptibility to Cutaneous Melanoma.

Authors:  David Tovar-Parra; Sebastián Ramiro Gil-Quiñones; John Nova; Luz D Gutiérrez-Castañeda
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

3.  Comparison of the effects of medical and surgical treatments in giant prolactinoma: a single-center experience.

Authors:  Soner Cander; Ozen Oz Gul; Eda Eylemer; Elif Gullulu Boz; Elif Gunes; Bahattin Hakyemez; Selcuk Yilmazlar; Canan Ersoy
Journal:  Hormones (Athens)       Date:  2021-07-08       Impact factor: 2.885

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.